LFB announces FDA approval of SEVENFACT®, a recombinant coagulation Factor VIIa
GLOBAL PLASMA LEADERS COLLABORATE TO ACCELERATE DEVELOPMENT OF POTENTIAL COVID-19 HYPERIMMUNE THERAPY
LFB SIGNS AGREEMENT WITH XENOTHERA TO MANUFACTURE FIRST CLINICAL BATCH OF XENOTHERA'S XAV-19 FOR THE TREATMENT OF CORONAVIRUS INFECTIONS INCLUDING COVID-19
COVID-19: LFB and its employees are mobilized to provide medicines for patients.
LFB's commitment to patients
Discover the LFB Arras plant under construction - September 2019
Bioproduction sites in France
of LFB’s products treat rare diseases
in the field
LFB's commitment to patients and to IRIS association.
LFB Arras plant under construction, in September 2019 in video
Living with peripheral neuropathies, a video supported by LFB
LFB Group corporate film 2019